Literature DB >> 20616810

The polarization of immune cells in the tumour environment by TGFbeta.

Richard A Flavell1, Shomyseh Sanjabi, Stephen H Wrzesinski, Paula Licona-Limón.   

Abstract

Transforming growth factor-beta (TGFbeta) is an immunosuppressive cytokine produced by tumour cells and immune cells that can polarize many components of the immune system. This Review covers the effects of TGFbeta on natural killer (NK) cells, dendritic cells, macrophages, neutrophils, CD8(+) and CD4(+) effector and regulatory T cells, and NKT cells in animal tumour models and in patients with cancer. Collectively, many recent studies favour the hypothesis that blocking TGFbeta-induced signalling in the tumour microenvironment enhances antitumour immunity and may be beneficial for cancer therapy. An overview of the current drugs and reagents available for inhibiting TGFbeta-induced signalling and their phase in clinical development is also provided.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20616810      PMCID： PMC3885992          DOI： 10.1038/nri2808

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN： 1474-1733            Impact factor:   53.106


  153 in total

1.  Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7.

Authors:  Massimo C Fantini; Christoph Becker; Giovanni Monteleone; Francesco Pallone; Peter R Galle; Markus F Neurath
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

Review 2.  Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009.

Authors:  Karl-Hermann Schlingensiepen; Reimar Schlingensiepen; Andreas Steinbrecher; Peter Hau; Ulrich Bogdahn; Birgit Fischer-Blass; Piotr Jachimczak
Journal:  Cytokine Growth Factor Rev       Date:  2005-12-27       Impact factor: 7.638

Review 3.  Up on the tightrope: natural killer cell activation and inhibition.

Authors:  Lewis L Lanier
Journal:  Nat Immunol       Date:  2008-05       Impact factor: 25.606

4.  p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance.

Authors:  Alessandra Saccani; Tiziana Schioppa; Chiara Porta; Subhra K Biswas; Manuela Nebuloni; Luca Vago; Barbara Bottazzi; Mario P Colombo; Alberto Mantovani; Antonio Sica
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

5.  Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB.

Authors:  Chiara Porta; Monica Rimoldi; Geert Raes; Lea Brys; Pietro Ghezzi; Diana Di Liberto; Francesco Dieli; Serena Ghisletti; Gioacchino Natoli; Patrick De Baetselier; Alberto Mantovani; Antonio Sica
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-17       Impact factor: 11.205

6.  Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated.

Authors:  Marta Torroella-Kouri; Risset Silvera; Dayron Rodriguez; Raul Caso; Alwi Shatry; Shannon Opiela; Dan Ilkovitch; Reto A Schwendener; Vijaya Iragavarapu-Charyulu; Yoslayma Cardentey; Natasa Strbo; Diana M Lopez
Journal:  Cancer Res       Date:  2009-05-19       Impact factor: 12.701

7.  Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients.

Authors:  June-Chul Lee; Kyung-Mi Lee; Dong-Wan Kim; Dae Seog Heo
Journal:  J Immunol       Date:  2004-06-15       Impact factor: 5.422

8.  Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment.

Authors:  Ilona Kryczek; Shuang Wei; Linhua Zou; Saleh Altuwaijri; Wojciech Szeliga; Jay Kolls; Alfred Chang; Weiping Zou
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

9.  Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers.

Authors:  Africa Wallace; Veena Kapoor; Jing Sun; Paul Mrass; Wolfgang Weninger; Daniel F Heitjan; Carl June; Larry R Kaiser; Leona E Ling; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

Review 10.  Differentiation of T regulatory cells by immature dendritic cells.

Authors:  M G Roncarolo; M K Levings; C Traversari
Journal:  J Exp Med       Date:  2001-01-15       Impact factor: 14.307
View more
  391 in total

1.  An antigen-specific semi-therapeutic treatment with local delivery of tolerogenic factors through a dual-sized microparticle system blocks experimental autoimmune encephalomyelitis.

Authors:  Jonathan J Cho; Joshua M Stewart; Theodore T Drashansky; Maigan A Brusko; Ashley N Zuniga; Kyle J Lorentsen; Benjamin G Keselowsky; Dorina Avram
Journal:  Biomaterials       Date:  2017-07-24       Impact factor: 12.479

2.  TCR signaling intensity controls CD8+ T cell responsiveness to TGF-β.

Authors:  Vidhyalakshmi Arumugam; Theresa Bluemn; Erin Wesley; Amanda M Schmidt; Taku Kambayashi; Subramaniam Malarkannan; Matthew J Riese
Journal:  J Leukoc Biol       Date:  2015-07-07       Impact factor: 4.962

3.  A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapy.

Authors:  Brynn B Duncan; Steven L Highfill; Haiying Qin; Najat Bouchkouj; Shannon Larabee; Peng Zhao; Iwona Woznica; Yuxin Liu; Youhua Li; Wengen Wu; Jack H Lai; Barry Jones; Crystal L Mackall; William W Bachovchin; Terry J Fry
Journal:  J Immunother       Date:  2013-10       Impact factor: 4.456

4.  TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells.

Authors:  Sarah S Donatelli; Jun-Min Zhou; Danielle L Gilvary; Erika A Eksioglu; Xianghong Chen; W Douglas Cress; Eric B Haura; Matthew B Schabath; Domenico Coppola; Sheng Wei; Julie Y Djeu
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-28       Impact factor: 11.205

5.  Defective TGF-β signaling in bone marrow-derived cells prevents hedgehog-induced skin tumors.

Authors:  Qipeng Fan; Dongsheng Gu; Hailan Liu; Ling Yang; Xiaoli Zhang; Mervin C Yoder; Mark H Kaplan; Jingwu Xie
Journal:  Cancer Res       Date:  2013-11-26       Impact factor: 12.701

6.  TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies.

Authors:  Tristan Courau; Djamel Nehar-Belaid; Laura Florez; Béatrice Levacher; Thomas Vazquez; Faustine Brimaud; Bertrand Bellier; David Klatzmann
Journal:  JCI Insight       Date:  2016-06-16

Review 7.  Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer.

Authors:  Taylor T Chrisikos; Yifan Zhou; Natalie Slone; Rachel Babcock; Stephanie S Watowich; Haiyan S Li
Journal:  Mol Immunol       Date:  2018-03-15       Impact factor: 4.407

8.  Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance.

Authors:  Gerald Willimsky; Karin Schmidt; Christoph Loddenkemper; Johanna Gellermann; Thomas Blankenstein
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

9.  A Milieu Molecule for TGF-β Required for Microglia Function in the Nervous System.

Authors:  Yan Qin; Brian S Garrison; Wenjiang Ma; Rui Wang; Aiping Jiang; Jing Li; Meeta Mistry; Roderick T Bronson; Daria Santoro; Charlotte Franco; Daisy A Robinton; Beth Stevens; Derrick J Rossi; Chafen Lu; Timothy A Springer
Journal:  Cell       Date:  2018-06-14       Impact factor: 41.582

10.  The adhesion molecule PECAM-1 enhances the TGF-β-mediated inhibition of T cell function.

Authors:  Debra K Newman; Guoping Fu; Tamara Adams; Weiguo Cui; Vidhyalakshmi Arumugam; Theresa Bluemn; Matthew J Riese
Journal:  Sci Signal       Date:  2016-03-08       Impact factor: 8.192
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.